Chemours Co (NYSE:CC) shares reached a new 52-week low on Monday . The company traded as low as $25.06 and last traded at $25.42, with a volume of 117473 shares trading hands. The stock had previously closed at $26.97.

A number of research analysts have weighed in on the company. Zacks Investment Research upgraded Chemours from a “sell” rating to a “hold” rating in a research note on Monday, March 18th. ValuEngine downgraded Chemours from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 1st. Susquehanna Bancshares restated a “neutral” rating and issued a $37.00 price target on shares of Chemours in a research note on Tuesday, February 19th. SunTrust Banks raised their price target on Chemours to $40.00 and gave the company a “hold” rating in a research note on Tuesday, February 19th. Finally, Citigroup restated a “buy” rating and issued a $43.00 price target on shares of Chemours in a research note on Wednesday, February 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $46.00.

The stock has a market cap of $4.15 billion, a PE ratio of 4.30, a P/E/G ratio of 0.39 and a beta of 2.20. The company has a debt-to-equity ratio of 5.18, a current ratio of 1.81 and a quick ratio of 1.04.

Chemours (NYSE:CC) last released its quarterly earnings data on Thursday, May 2nd. The specialty chemicals company reported $0.63 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.93 by ($0.30). Chemours had a net margin of 12.60% and a return on equity of 87.75%. The business had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.52 billion. During the same period in the previous year, the business earned $1.41 earnings per share. The business’s quarterly revenue was down 20.5% on a year-over-year basis. On average, equities research analysts predict that Chemours Co will post 4.22 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Thursday, May 16th will be given a $0.25 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 4.10%. Chemours’s payout ratio is 17.64%.

In other news, VP Mark Newman sold 59,210 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $38.26, for a total value of $2,265,374.60. Following the completion of the sale, the vice president now directly owns 94,261 shares of the company’s stock, valued at $3,606,425.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Paul Kirsch sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $38.66, for a total value of $386,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 101,924 shares of company stock valued at $3,924,730. Insiders own 2.34% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Live Your Vision LLC lifted its holdings in Chemours by 6.3% during the 1st quarter. Live Your Vision LLC now owns 4,993 shares of the specialty chemicals company’s stock worth $198,000 after purchasing an additional 295 shares during the last quarter. Financial Architects Inc lifted its holdings in Chemours by 39.2% during the 4th quarter. Financial Architects Inc now owns 1,421 shares of the specialty chemicals company’s stock worth $40,000 after purchasing an additional 400 shares during the last quarter. Gulf International Bank UK Ltd lifted its holdings in Chemours by 1.0% during the 1st quarter. Gulf International Bank UK Ltd now owns 40,350 shares of the specialty chemicals company’s stock worth $1,499,000 after purchasing an additional 400 shares during the last quarter. TCI Wealth Advisors Inc. lifted its holdings in Chemours by 27.5% during the 1st quarter. TCI Wealth Advisors Inc. now owns 1,916 shares of the specialty chemicals company’s stock worth $71,000 after purchasing an additional 413 shares during the last quarter. Finally, Crossmark Global Holdings Inc. lifted its holdings in Chemours by 2.2% during the 1st quarter. Crossmark Global Holdings Inc. now owns 23,040 shares of the specialty chemicals company’s stock worth $856,000 after purchasing an additional 500 shares during the last quarter. 82.18% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2019/05/15/chemours-cc-reaches-new-52-week-low-at-25-06.html.

About Chemours (NYSE:CC)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Recommended Story: What is the Dividend Aristocrat Index?

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.